Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe.
Clin Microbiol Infect
; 9(6): 475-88, 2003 Jun.
Article
en En
| MEDLINE
| ID: mdl-12848722
ABSTRACT
OBJECTIVE:
To evaluate the activity of old and newer antianaerobic drugs against clinical isolates of Bacteroides fragilis group strains from different parts of Europe.METHODS:
Bacteroides fragilis group isolates from 37 laboratories in 19 countries were biochemically characterized. The MICs of seven antimicrobial agents were determined by the agar dilution method as recommended by the NCCLS. Production of beta-lactamase was detected by nitrocefin.RESULTS:
There were 1284 B. fragilis group isolates included in the study. Abdominal infections and wounds were the most common sources of isolation and B. fragilis was the dominating species. Ninety-nine percent of the strains were resistant to ampicillin (breakpoint 2 mg/L), 6% to cefoxitin (64 mg/L), 15% to clindamycin (8 mg/L) and 9% to moxifloxacin (8 mg/L). Less than 1% were resistant to imipenem (16 mg/L), piperacillin-tazobactam (128 mg/L) and metronidazole (32 mg/L). Ninety-six percent of the isolates were beta-lactamase producers.CONCLUSIONS:
Antimicrobial resistance among the B. fragilis group is increasing.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Bacteroides fragilis
/
Antibacterianos
País/Región como asunto:
Europa
Idioma:
En
Revista:
Clin Microbiol Infect
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
/
MICROBIOLOGIA
Año:
2003
Tipo del documento:
Article
País de afiliación:
Suecia